Jacob Davies

Jacob Davies

Auto-generated profile, based on publicly available information

Jacob Davies

Bangor University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
KDKodchawan Doungsong
Kodchawan Doungsong
JDJacob Davies
Jacob Davies
VEVictory Ezeofor
Victory Ezeofor
Llinos Haf SpencerLlinos Haf Spencer
Llinos Haf Spencer
NWNefyn Williams
Nefyn Williams
OTon behalf of the FEMuR III team
on behalf of the FEMuR III team
Summary The FEMuR III economic evaluation presents costs and consequences of the intervention compared with usual care at 52-week follow-up. There was no evidence of clinical effectiveness in terms of improvement of quality of life, and the total health service costs were higher in the intervention group. Purpose To explore the costs and consequences of the new FEMuR III intervention compared to usual care after hip fractures. Methods This cost-consequence analysis accompanies the FEMuR III randomised controlled trial using a micro-costing approach. The main outcome measures in this economic evaluation were healthcare service use, costs, and quality of life over 12 months, from both National Health Service and wider societal perspectives. Quality of life was measured using the EuroQoL-5D-3L. Results The mean cost of delivering the intervention was £444 per participant. For participants with complete EQ-5D data (n = 142), both groups showed improvement in EQ-5D index score, moving scores closer to UK norms. Participants in the intervention group gained 0.02 (95% CI: − 0.036, 0.076) more quality-adjusted life years (QALYs) than the usual care group. However, this was not statistically significant (p value = 0.312). For imputed cases, participants in the intervention group gained less QALYs than the usual care by 0.01 (95% CI: − 0.056, 0.030). For participants with complete cost data (n = 115), at 52-week follow-up, mean health service use costs were higher in the intervention group from both perspectives. Conclusions The mean health service use costs were higher in the intervention group due to longer inpatient stays. There was no significant difference in QALYs between both groups. The trial was affected by the COVID-19 pandemic, and this goes some way to explaining the large proportion of missing data (40%). Trial registration ISRCTN28376407.

29 December 2025 in The European Journal of Health Economics
Verified
Journal Article
Open access
PDF file
MMMaureen Rutten-van Mölken
Maureen Rutten-van Mölken
HWHolly Whiteley
Holly Whiteley
BBBalázs Babarczy
Balázs Babarczy
JDJacob Davies
Jacob Davies
LGLucas Goossens
Lucas Goossens
RERhiannon Tudor Edwards
Rhiannon Tudor Edwards
Background Smart Capacitating Investments (SCI) have been proposed as a means of mobilizing extra public and private investments in health promotion and disease prevention, but the concept needs clarification and development. Aim To develop the concept SCI and explore available and emerging SCI models that could generate additional resources for health promotion and prevention. Methods i) a rapid scoping review to explore existing examples of innovative investment in health promotion and disease prevention, ii) horizon scanning of recent/emerging examples of innovative investment models via expert interviews and web searches, and iii) a realist-informed synthesis of literature and interview-results to investigate investor motivations, barriers, and enablers for different forms of SCI. Results We present a definition of SCI that stresses these unconventional investments are either financial or non-financial, that they are made by reallocating and pooling public funds within the health sector or by involving other non-health public sectors, private not-for-profit or for-profit social impact investors. SCI models aim to sustainably enhance individual and community capacity for healthier behaviors, or to address determinants of health. We describe the broad range and nature of SCI via a classification and typology of SCI models. Social Impact Bonds were found to be the most frequently applied model across all levels of prevention. For successful implementation of blended SCI models by public–private partnerships, significant government involvement was important. Conclusion SCIs are diverse and novel, and they have potential to bring about change, particularly if backed by government to attract private capital and ensure rigorous evaluation.

28 January 2023 in medRxiv
Verified
Preprint
Open access
PDF file
Llinos Haf SpencerLlinos Haf Spencer
Llinos Haf Spencer
AHAnnie Hendry
Annie Hendry
AMAbraham Makanjuola
Abraham Makanjuola
BABethany Anthony
Bethany Anthony
JDJacob Davies
Jacob Davies
AEAdrian G Edwards
Adrian G Edwards
Previous research has categorised symptoms of COVID-19 / Long COVID into 12 thematic areas including: fever, myalgia, fatigue, impaired cognitive function, and that COVID-19 survivors had reduced levels of physical function, activities of daily living, and health-related quality of life. Our aim was to review the evidence for interventions or best practice to support people with Long COVID, or similar post-viral conditions characterised by fatigue, to return to normal activities. Evidence was included from guidelines, systematic reviews (SR), and primary studies. The primary studies focussed on Long COVID (LC) indicated that there should be a needs-based focus to care for those with LC. Consideration should be given to individuals living with LC in the same way as people with disabilities are accommodated in terms of workplace adjustment. Two SRs indicated that non-pharmaceutical interventions (NPIs) for patients with LC or chronic fatigue syndrome could help improve function for activities of daily life. However, the third, most recent SR, concluded that there is a lack of robust evidence for NPIs. LC fatigue management methods may be beneficial under certain conditions. One SR reported work capability as an outcome however they did not find any studies which evaluated the impact of interventions on return to work/ normal life. One primary study, on individuals with CFS, described a written self-management programme. Following this intervention there was an 18% increase in the number of patients in employment. Policy and practice implications: Long COVID is still being established as a post-viral condition with many symptoms. Patient-centred treatment options such as occupational therapy, self-management therapy and talking therapy may be considered in the same way as for other debilitating conditions. Return-to-work accommodations are needed for all workers unable to return to full-time employment. Due to the nature of the studies included, there was little reported evidence of effectiveness of getting individuals back into their normal activities. Funding statement: The Bangor Institute for Health and Medical Research was funded for this work by the Wales COVID-19 Evidence Centre, itself funded by Health & Care Research Wales on behalf of Welsh Government. Rapid Review Details: Review conducted by: Bangor Institute for Health and Medical Research (BIHMR), Bangor University. Review Team: ▪ Dr Llinos Haf Spencer, l.spencer@bangor.ac.uk ▪ Dr Annie Hendry, a.hendry@bangor.ac.uk ▪ Mr Abraham Makanjuola, a.makanjuola@bangor.ac.uk ▪ Ms Bethany Fern Anthony, b.anthony@bangor.ac.uk ▪ Mr Jacob Davies, jacob.davies@bangor.ac.uk ▪ Ms Kalpa Pisavadia, kalpa.pisavadia@bangor.ac.uk ▪ Professor Dyfrig Hughes, d.a.hughes@bangor.ac.uk ▪ Professor Deb Fitzsimmons, d.fitzsimmons@bangor.ac.uk ▪ Professor Clare Wilkinson, c.wilkinson@bangor.ac.uk ▪ Professor Rhiannon Tudor Edwards, r.t.edwards@bangor.ac.uk Review submitted to the WCEC on: 11 January 2023 Stakeholder consultation meeting: 8 th November 2022 Rapid Review report issued by the WCEC in: January 2022 WCEC Team: Adrian Edwards, Ruth Lewis, Alison Cooper and Micaela Gal involved in drafting the Topline Summary and editing. This review should be cited as: RR00042_ Wales COVID-19 Evidence Centre Disclaimer: The views expressed in this publication are those of the authors, not necessarily Health and Care Research Wales. The WCEC and authors of this work declare that they have no conflict of interest. TOPLINE SUMMARY: What is a Rapid Review?: Our rapid reviews (RR) use a variation of the systematic review (SR) approach, abbreviating or omitting some components to generate the evidence to inform stakeholders promptly whilst maintaining attention to bias. They follow the methodological recommendations and minimum standards for conducting and reporting RR, including a structured protocol, systematic search, screening, data extraction, critical appraisal, and evidence synthesis to answer a specific question and identify key research gaps. They take 1 to 2 months, depending on the breadth and complexity of the research topic/question(s), extent of the evidence base, and type of analysis required for synthesis. Who is this summary for?: Policymakers in Welsh Government to plan and deliver services for individuals with Long COVID as they re-enter training, education, employment, and informal caring responsibilities. Background / Aim of Rapid Review: Previous research has categorised symptoms of COVID-19/Long COVID into 12 thematic areas including: fever, myalgia, fatigue, impaired cognitive function, and that COVID-19 survivors had reduced levels of physical function, activities of daily living, and health-related quality of life (Amdal et al., 2021; de Oliveira Almeida et al., 2022). NICE guidelines highlight the impact of the condition on quality of life and the challenge of determining best practice based on the current evidence (National Institute for Health and Care Excellence et al., 2022). Treatments for other post-viral syndromes may also apply to people living with Long COVID (Wong and Weitzer, 2021). Our aim was to review the evidence for interventions or best practice to support people with Long COVID, or similar post-viral conditions characterised by fatigue, to return to normal activities (including return to the workforce, education, childcare, or housework). Key Findings: Evidence was included from guidelines (n=3), systematic reviews (SRs) (n=3), and primary studies (n=4). Extent of the evidence base: ▪ Two SRs included non-pharmacological interventions for Long COVID or post-viral syndromes, including Long COVID (Chandan et al., 2022; Fowler-Davis et al., 2021). The remaining SR focused on interventions for Chronic Fatigue Syndrome (CFS). ▪ The four primary studies were conducted in the UK, USA, Norway, and Turkey. The SRs included studies from across Europe, Asia, Africa, and Australasia. ▪ Included SRs and primary studies evaluated non-pharmaceutical interventions, including fatigue management, exercise therapy, Cognitive Behavioural Therapy (CBT), workplace support, self-management, sleep therapy, music therapy, and counselling. ▪ Two relevant guidelines were identified for Long COVID and one for ME/CFS. The Long COVID guideline was aimed at employers, and the ME/CFS guideline was aimed at service providers and users. Recency of the evidence base: ▪ Included papers were from 2014 to 2022. Evidence of effectiveness: ▪ The primary studies focussed on Long COVID indicated that there should be a needs-based focus to care for those with Long COVID (Lunt et al., 2022; Skilbeck, 2022; Wong et al., 2022). Consideration should be given to individuals living with Long COVID in the same way as people with disabilities are accommodated in terms of workplace adjustment (e.g. part-time hours, working from home, or hybrid working). ▪ Two SRs indicated that non-pharmaceutical interventions for patients with Long COVID or CFS could help improve function for activities of daily life (Fowler-Davis et al., 2021; Larun et al., 2019). However, the third and most recent SR concluded that there is a lack of robust evidence for non-pharmaceutical interventions (Chandan et al., 2022). ▪ Long COVID fatigue management by exercise therapy, electrical nerve stimulation, sleep and touch therapy, and behavioural self-management may be beneficial when: physical and psychological support is delivered in groups, people can plan their functional response to fatigue, strengthening rather than endurance is used to prevent deconditioning, fatigue is regarded in the context of an individual’s lifestyle and home-based activities are used (Fowler-Davis et al 2021). ▪ One SR (Chandan et al 2022) reported work capability as an outcome however they did not find any studies which evaluated the impact of interventions on return to work/ normal life. ▪ One primary study concentrated on individuals with CFS (Nyland et al., 2014). Nyland et al. (2014) described a written self-management programme featuring active coping (with CFS) strategies for daily life. Following this intervention, there was an 18% increase in the number of patients in employment (from baseline to follow-up) (Nyland et al., 2014). Best quality evidence: ▪ The three SRs (Chandan et al., 2022; Fowler-Davis et al., 2021; Larun et al., 2019) were of high quality, as was one of the cohort studies (Lunt et al., 2022). Policy Implications: ▪ Long COVID is still being established as a post-viral condition with many symptoms. The Welsh Government may seek to consider patient-centred treatment options such as occupational therapy, self-management therapy and talking therapy (such as Cognitive Behavioural Therapy) in the same way as for other debilitating conditions including ME/CFS. ▪ Return-to-work accommodations are needed for all workers unable to return to full-time employment. ▪ Due to the nature of the studies included, there was little reported evidence of effectiveness of getting individuals back into their normal activities. Strength of Evidence: Confidence in the findings is low. Only four primary studies reported outcomes relating to work capacity and return to normal activities such as childcare and housework.

21 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
KPKalpa Pisavadia
Kalpa Pisavadia
BABethany Anthony
Bethany Anthony
JDJacob Davies
Jacob Davies
SRSofie Roberts
Sofie Roberts
RGRachel Louise Granger
Rachel Louise Granger
RLRuth Lewis
Ruth Lewis
The UK is expected to see a 60% increase in first-time strokes over the next 20 years. This translates to about 2.1 million stroke survivors living in the UK by 2035. Life after stroke services aim to support peoples physical and emotional state, are complimentary to rehabilitation and take a non-medical holistic approach to living well after a stroke. This rapid review aimed to identify evidence on the cost-effectiveness of life after stroke services, and the impact of these interventions on health or social care resource use. The review included evidence from 12 studies (7 economic evaluations and 5 randomised controlled trials), published between January 2000 and August 2024. The economic evaluations assessed a number of interventions to support stroke survivors, their families and caregivers. Two of the randomised controlled trials were partial economic evaluations, reporting on cost and resource use data related to training caregivers, and an arts and health-based intervention. The other three trials reported on resource use but not cost data, and assessed family support interventions, and a telehealth intervention to assist stroke survivors and their carers. There was a lack of evidence on the cost-effectiveness of life after stroke as a comprehensive service. However, this review identified evidence on the cost-effectiveness and resource utilisation of specific interventions within these services. Findings include that a community-based Individual Management Program for post-stroke survivors was cost-effective from a societal perspective at 24-month follow-up. A carer training intervention, delivered whilst the stroke patient was in hospital, was associated with a reduction in health and social care resource use when evaluated at a single hospital. However, this intervention was not cost-effective when rolled out and assessed across multiple hospitals. Other findings included that a combination of speech and language therapy with voluntary support services had a lower cost per session compared to NHS speech and language therapy alone. Family support organiser interventions for stroke survivors and carers were associated with reduced healthcare utilisation. To fully understand the effectiveness and cost-effectiveness of life after stroke interventions, research is needed to assess potential long-term impacts. A reduction in resource use may be associated with cost savings and reduced burden on the NHS. However, an increase in health care and social care use may also be appropriate due to better signposting or identification of peoples’ needs. While traditional cost-effectiveness analysis provides a valuable framework for evaluating healthcare interventions, it may not fully capture the individual experiences of stroke survivors or the broader impact on their ongoing recovery, wellbeing and the lives of their carers. Future research should seek to quantify the effects of life after stroke support on patients and carers. Evidence is also needed on the cost-effectiveness of supporting stroke survivors in returning to the workforce. Many of the sample sizes in the included studies lacked ethnic diversity. Stroke trials need strategies to achieve equity of access. This review focused on evidence of cost-effectiveness and resource utilisation. Decisions relating to policy and practice should also consider evidence on clinical effectiveness and patient preferences. Funding Statement: The authors were funded for this work by the Health and Care Research Wales Evidence Centre, itself funded by Health and Care Research Wales on behalf of Welsh Government. Report Contributors: Review Team: Kalpa Pisavadia, Bethany Fern Anthony, Jacob Davies, Sofie Roberts, Rachel Granger, Llinos Haf Spencer, Elizabeth Gillen, Juliet Hounsome, Jayne Noyes, Deborah Fitzsimmons, and Rhiannon Tudor Edwards. Methodological Advice: Ruth Lewis Evidence Centre Team: Ruth Lewis, Adrian Edwards, Alison Cooper, Micaela Gal and Elizabeth Doe involved in Stakeholder engagement, review of report and editing. Public Partner: Robert Hall Stakeholder(s): Angela Contestabile, Heidi James, Lynn Preece, Llinos Wyn Parry, Katie Chappelle, Jonathan Hewitt. Evidence need submitted to the Evidence Centre: 30.10.2023 Initial Stakeholder Consultation Meeting: 29.04.24 Final Report issued: June 2025 The review should be cited as: Health and Care Research Wales Evidence Centre. A rapid review of cost-effectiveness of life after stroke services and the impact of these services on health and social care resource use_(RR0027). June 2025. Disclaimer: The views expressed in this publication are those of the authors, not necessarily Health and Care Research Wales. The Health and Care Research Wales Evidence Centre and authors of this work declare that they have no conflict of interest. EXECUTIVE SUMMARY: What is a Rapid Review?: Our rapid reviews use a variation of the systematic review approach, abbreviating or omitting some components to generate the evidence to inform stakeholders promptly whilst maintaining attention to bias. Who is this Rapid Review for?: This Rapid Review was conducted as part of the Health and Care Research Wales Evidence Centre Work Programme. The review question was suggested by representatives of the Stroke Association UK. Background / Aim of Rapid Review: The UK is expected to see a 60% increase in first-time strokes over the next 20 years. This translates to about 2.1 million stroke survivors living in the UK by 2035. Approximately 70,000 stroke survivors are currently living in Wales. Life after stroke services take a non-medical holistic approach to living well after a stroke and are complimentary to rehabilitation. Life after stroke services encompass services that aim to support people’s physical and emotional state. Some of these services are specific to communication and emotional support, providing tools and information, reassurance, coaching and peer support. Life after stroke services have the potential to reduce the cost burden to health and social care. This rapid review aimed to identify evidence on the cost-effectiveness of life after stroke services and the impact of these interventions on health or social care resource use (it did not review the evidence on the clinical effectiveness or peoples lived experience of life after stroke services). Results of the Rapid Review: The evidence base: The review included evidence from studies published between January 2000 and August 2024 (at the time when the searches were conducted). Of the 12 studies included, seven were economic evaluations, and five were randomised controlled trials reporting on cost and or resource use data only. The seven economic evaluations assessed the following interventions: a needs assessment tool for caregivers (Patchwood et al, 2021); training for caregivers (Forster et al, 2013); an exercise and education reintegration programme for stroke survivors and their families (Harrington et al, 2010), a community-based Individual Management Program for post-stroke survivors (Orman et al, 2024); combined speech and language therapy and support services for stroke survivors and their families (van der Gaag and Brooks, 2008); peer-befriending for psychological distress (Flood et al, 2022), and a post-discharge structured assessment (Forster et al, 2015). Two randomised controlled trials were partial economic evaluations which reported on cost and resource use data. These studies specifically related to the following interventions: training caregivers (Kalra et al, 2004); and an arts and health-based intervention (Ellis-Hill et al, 2019). The remaining three randomised controlled trials reported on resource use but not cost data and assessed family support organiser service (Mant et al, 2000; Tilling et al, 2005), and a telehealth support intervention designed to assist stroke survivors and their carers (Bishop et al, 2014). Key findings: This review highlighted a lack of studies evaluating the cost-effectiveness of life after stroke as a comprehensive service as per the national stoke model, particularly when delivered as intended in a holistic multicomponent format. However, this review identified evidence on the cost-effectiveness and resource utilisation of specific interventions within these services, that support both stroke survivors and carers. A community-based Individual Management Program for post-stroke survivors was found to be cost-effective from a societal perspective at 24-month follow-up. A combination of speech and language therapy with voluntary support services had a lower cost per session than reported costs for equivalent NHS services However, cost-effectiveness was not assessed in this study A telehealth support intervention was associated with a reduction in healthcare utilisation. A caregiver training programme, delivered whilst the stroke patient was still in hospital, was associated with a reduction in health and social care resource use when evaluated at a single hospital. However, this intervention was not found to be cost-effective when rolled out and assessed across multiple hospitals. A community-based arts and health group intervention led to a reduction in outpatient contacts and home care worker contacts compared to usual care. A Family Support Organiser service was associated with a reduction in physiotherapy contact, but the use of other services were comparable with usual care. The addition of a new post-discharge system to an existing community-based Stroke Care Coordinators service was not cost-effective from either a health or societal perspective when compared to the Stroke Care Coordinator usual practice. Peer-befriending was found to be more costly and less effective than usual care alone. The use of a Carer Support Needs Assessment Tool (CSNAT) was not cost-effective compared to usual care. The cost per patient of a community-based combined exercise and education reintegration programme was greater than that of the control group. Policy and Practice Implications: There is some evidence that interventions such as Individual Management Programme; telehealth support, community-based arts and health group, Family Support Organiser, and caregiver training can be cost-effective or lead to a reduction in service utilisation. While the gold standard model of traditional cost-effectiveness analysis proves a robust and valuable framework for assessing the cost-effectiveness of healthcare interventions, it does not capture the individual impact on the recovery of a stroke survivor and the ongoing health and wellbeing of them or their family. This review focused on evidence of cost-effectiveness and resource utilisation, which are helpful in the context of resource allocation for future roll-out of services, however, decisions relating to policy and practice must also consider the wider evidence base on clinical effectiveness and patient preferences going forward. Although a reduction in resource use may be associated with cost savings and reduced burden on the NHS, importantly, an increase in health care and social care use may also be appropriate due to better signposting or identification of peoples’ needs. Research Implications and Evidence Gaps: Further research is needed on cost-effectiveness of life after stroke as a comprehensive service as per the national stoke model To fully understand the effectiveness and cost-effectiveness of life after stroke interventions, research is needed to assess potential long-term impacts. Evidence is needed on the cost-effectiveness of supporting stroke survivors in returning to the workforce. The timing of life after stroke interventions appeared to be important in terms of how they are received by stroke survivors, their carers and their families. Many of the samples in the included studies lacked ethnic diversity. Stroke trials need strategies to achieve equity of access, given that a large portion of UK stroke admissions are from Black, Asian and minority ethnic communities (Office for National Statistics, 2021). Economic considerations: The average cost to society per stroke survivor in the first year post-stroke in the UK is £45,409. The key drivers of this cost are informal care and lost productivity costs (Stroke Association, 2020). Appropriate and timely post-stroke support for stroke survivors, their families and or caregivers could help alleviate some of this economic impact. Stroke costs NHS Wales £220 million per year. When considering a wider societal economic cost, this figure rises to £1.6 billion per year. If current trends persist with no action taken, this figure is forecast to increase to £2.8 billion per annum by 2035 (Welsh Government, 2024b). Glossary: Economic evaluation: an assessment of the costs and effects of alternate healthcare interventions. The aim of an economic evaluation is to help decision makers maximise the level of health benefits relative to the finite resources available. Health and Social Care resource use or utilisation: refers to the use of healthcare resources by end users (patients) and intervention deliverers. This can take the form of contacts with health professionals across health and social care, medicines or healthcare consumables used. In economic evaluations, resource use is collected, and costs are assigned to them to identify the costs an intervention places on the healthcare system. Cost-effectiveness analysis: costs are compared with a treatment’s common therapeutic goal, expressed in terms of one main outcome measured in natural units (e.g., improvement in blood pressure or cholesterol level). These outcomes are typically condition-specific, meaning comparison within conditions is possible, but difficulty arises in comparing between conditions. Cost-utility analysis: a method of evaluation that measures health benefits in preference-based, non-monetary units such as Quality Adjusted Life Years (QALYs) or Disability Adjusted Life Years (DALYs). These units are helpful for economic evaluation as they are generic and can be applied across conditions, allowing for comparison between conditions. Full economic evaluation: is an economic evaluation that compares both the costs and effects of alternate healthcare interventions. The examples of cost-effectiveness and cost-utility above reflect full economic evaluations as they analyse both costs and outcomes of interventions. Partial economic evaluation: is an economic evaluation that does not compare both the costs and effects of alternate healthcare interventions. A common partial economic evaluation is a cost-analysis that presents the costs of interventions only, with no consideration of effects. Partial economic evaluations are sometimes conducted within or alongside randomised controlled trials. However, the conduct of partial economic evaluations are not limited to randomised controlled trial study designs, with alternatives including economic evaluations alongside natural experiments or economic modelling studies which often utilise sources of data from previous literature in addition to or instead of collecting primary data. Randomised controlled trial: a study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug, treatment or other intervention. One group (the intervention group) has the intervention being tested, the other (the comparison or control group) has an alternative intervention, a dummy intervention (placebo) or no intervention at all. The groups are followed up at set time periods to see how effective the experimental intervention was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. Randomised controlled trials are the highest standard of research trials as their design helps to reduce biases that may impact the findings. Randomised controlled trials with partial economic evaluations: are a study type that follows the randomised controlled trial methodology. Randomised controlled trials with cost comparisons collect information on the costs associated with the interventions studied to allow for comparison across alternate interventions not just based on clinical effect but also costs. Within-trial economic evaluation: is a full economic evaluation of the costs and effects of healthcare interventions that are being studied as part of a clinical trial. The primary aim of clinical trials is typically a measurement of clinical effect of administering an intervention (e.g., change in blood pressure). These clinical effects of the intervention are then assessed together with the costs of the intervention in the economic evaluation. Cost-consequence analysis: Is a form of partial economic evaluation that presents the disaggregated costs and outcomes of an intervention. Statistical significance: a statistically significant result is one that is deemed to be down to a true effect rather than random chance. It is a way to determine if a relationship between variables is caused by something other than chance.

3 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CEClare England
Clare England
ANAntonia Needham-Taylor
Antonia Needham-Taylor
NBNathan Bromham
Nathan Bromham
JHJuliet Hounsome
Juliet Hounsome
EGElizabeth Gillen
Elizabeth Gillen
RLRuth Lewis
Ruth Lewis
Outward medical tourism is when people seek medical treatment in a different country to the one they live in. There are concerns that people travelling abroad for surgery may be at risk of complications when they return home. This review aimed to identify all the studies that describe the impact on the UK NHS of patients who require follow-up care due to outward medical tourism for elective surgery and report on complications, costs and benefits. The review included evidence available until December 2024. 37 studies were included that described patients who were treated in the NHS for complications arising from elective surgery conducted abroad. 35 were case series or case reports, 19 relating to bariatric surgery, 15 to cosmetic surgery and 1 to ophthalmic surgery. 2 were surveys of plastic surgeons practicing in the NHS. 14 studies included a cost analysis. The case series and case reports included a total of 655 patients treated by the NHS between 2006 to 2024 for post-operative complications in specific hospitals. Not all studies reported all outcomes of interest. For the studies that reported demographic data, most patients were female (90%). The most common destination for surgery was Turkey (61%). For bariatric surgery tourism, abdominal pain, vomiting, inability to swallow and malnutrition were cited as presenting symptoms, with gastric leak being the most common diagnosis. Over a third of patients had to have a reversal or revision of the bariatric procedure. For cosmetic surgery tourism, the most common complications were infection and reopening of the surgical wound, with 57% of patients receiving antibiotics. No deaths were reported by any of the studies, although there was evidence that some patients needed complex treatment involving long hospital stays and multiple surgical interventions. Just over a half of patients required at least one investigation or intervention under local or general anaesthetic. Very low certainty of evidence indicates that costs to the NHS from outward medical tourism for elective surgery ranges from £1,058 to £19,549 per patient in 2024 prices. We found no studies that reported on benefits of outward medical tourism. Awareness-raising campaigns and interventions are warranted to inform members of the public considering going abroad for surgery about the potential for complications. There is a need for a systematic approach to collecting information on the impact on the UK NHS of treating complications arising from outward medical tourism for elective surgery and the associated costs. We still do not know how many people resident in the UK go abroad for elective surgery or how many people subsequently have complications. Without this data we cannot fully understand the amount of risk that people seeking surgery abroad are taking. Funding statement The authors and their Institutions were funded for this work by the Health and Care Research Wales Evidence Centre, itself funded by Health and Care Research Wales on behalf of Welsh Government.

10 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MKMeg Kiseleva
Meg Kiseleva
JHJuliet Hounsome
Juliet Hounsome
MMMala Mann
Mala Mann
Abubakar Sha'abanAbubakar Sha'aban
Abubakar Sha'aban
RRRiya Reji
Riya Reji
RLRuth Lewis
Ruth Lewis
Suicide deaths are tragic events and those that occur in public places have an impact not only on the deceased person and their family and friends, but also on members of the public. Having up-to-date information about the effectiveness of interventions allows policymakers and organisations managing locations of concern to choose the most appropriate evidence-based suicide prevention strategies for specific locations. This rapid review was conducted to help inform the development of Welsh national guidance. The review included literature published since 2014. 24 studies were identified, and these were conducted in the UK, Australia, South Korea, Canada, USA, Denmark and Japan. The studies covered railway or underground stations, bridges, cliffs or other natural heights, tall buildings, and other types of locations. Surveillance technologies as a means of increasing opportunity for third-party intervention showed the most promise, although the evidence of their effectiveness was limited. In one study, having more closed-circuit television (CCTV) units was associated with fewer suicides at railway stations. Another study that tested a set of interventions including CCTV, infrared security fences, and a suicidal behaviour recognition and alert system, provided some promising initial descriptive data that showed an increase in the number of prevented suicides. Three other studies showed that there was no change in outcomes following the installation of interventions including surveillance technologies. Based on the assessment of the overall body of the evidence, there is a low level of confidence in the findings related to surveillance technologies because of the quality and designs of the studies. Promotion of suicide helplines as an intervention aimed at increasing opportunities for help seeking was examined in seven studies. Two studies reported that the number of suicides increased after the introduction of the intervention. Three studies, of which two examined a set of interventions including helplines, observed no change. In two studies the effect could not be determined. There is a low level of confidence in the evidence for this outcome. Other interventions evaluated included staff training; deployment of specialist staff; campaigns encouraging bystanders to intervene; a crisis café; blue lights at railway stations; suicide prevention messages, memorials, or notes other than official crisis line signage; spinning rollers at the top of fences that prevent gripping; and others. The effect of these interventions could not be determined with certainty but some of them appeared promising and warrant further research. More robust evaluations are needed before any of the interventions reviewed here can be recommended for implementation. To create a better evidence base, high-quality evaluations should be supported and encouraged. Future research should examine which interventions work for who and in what circumstances.